Doxazosin and Meloxicam Combination Therapy for BPH Treatment With Luts

Abstract

Objective: To compare the efficacy of combination therapy of 4 mg doxazosin + 15 mg meloxicam with 4 mg doxazosin single therapy for benign prostate hyperplasia (BPH) patients with lower urinary tract symptoms (LUTS). Materials & Methods: A prospective, randomized and double blind study with total of 22 BPH patients with LUTS were randomized to receive 4 mg doxazosin + placebo once daily for 6 weeks or a combination of 4 mg doxazosin + 15 mg meloxicam once daily for 6 weeks. Inclusion criteria included IPSS ≥ 8, age > 50 years, prostate blood flow grade II. Therapeutic efficacy was assessed by comparing changes in IPSS, maximal urinary flow (Q-max) and changes in prostate blood flow between baseline and immediately after 6 weeks of therapy. Results: There was no significant difference in IPSS change between the two treatment groups (delta IPSS 4 ± 1.1 versus 3.7 ± 1.5, p = 0.630). There was a significant difference in Q-max changes between the two groups (delta Q-max 4 ± 1.5 versus 2.1 ± 0.7, p < 0.001). In group therapied with 4 mg doxazosin + 15 mg meloxicam prostate blood flow decreased from grade II to grade I in 9 of 11 patients (81%). Whereas, in the treatment group of 4 mg doxazosin + placebo no reduction was found in prostate blood flow. Conclusion: Combination therapy of 4 mg doxazosin + 15 mg meloxicam once daily for 6 weeks is better than 4 mg doxazosin therapy alone in improving Q-max and decreasing prostate blood flow in BPH patients with LUTS.Keywords: Benign prostate hyperplasia, inflammation, COX-2 inhibitors.

Comparison of meloxicam, tamsulosin and combination of both drugs with 16 Fr and 20 Fr catheter on trial without catheter successfulness in patients with benign prostatic hyperplasia

“…24 Combination therapy of meloxicam 15 mg and doxazosin 4 mg per oral once daily for six weeks was better in increasing Qmax and decreasing prostate blood flow in BPH patients with LUTS. 19 In a systematic review and meta-analysis of NSAIDs effects in LUTS BPH patient it was concluded that there were improvements in LUTS and urinary emissions as a result of NSAID administration. No serious adverse effects found.…”

“…18 Combination of oral meloxicam 15 mg and doxazosin 4 mg once daily for six weeks increase the maximum urine flow rate (Qmax) and decrease prostate blood flow in BPH patients with LUTS. 19 A systematic review and meta-analysis of non steroid anti-inflammation drugs (NSAID) effect by Kahokehr et al (2013) concluded that there were improvements in LUTS and urinary emissions as a result of NSAID administration. No serious adverse effects on NSAID administration is shown.…”